Apr 6, 2026 · 23m · tbpn
The Truth Behind the “Solo Founder Billion Dollar Company”
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
Hosts John Coogan and his co-host critically deconstruct the claim that MedV is a billion-dollar solo-founder telehealth company, exposing its outsourced infrastructure, deceptive advertising tactics, and regulatory liabilities before contrasting it with authentic high-margin solo creator models.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. The hosts hold 99.5% of the talking time here. How this is scored →
speaking balance: gold is the hosts, purple is the guest (3 minute bins)
In a universally collaborative episode, Hays playfully challenges Coogan's clarification regarding Balatro being banned for gambling aesthetics rather than real wagering.
Hardest push from the hosts ▶ 2:15 Rejecting the revenue-as-valuation presuppositionCoogan explicitly pushes back against the media's framing that 1.8 billion in revenue automatically equates to a billion-dollar company without evaluating margins and durability.
Biggest teaching moment ▶ 8:05 Hays elaborating on zero enterprise value playsHays explains the business model of anonymous founders in the nicotine space scaling revenue rapidly while leaving zero terminal enterprise value due to regulatory baggage.
The host holds their own ▶ 6:58 Firsthand regulatory breakdown from Lucy NicotineCoogan leverages his operational experience founding Lucy to explain FDA tobacco versus pharmaceutical cessation classifications and the high stakes of warning letters.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The hosts as informed peer | Guest teaching | Guest disagreement | The hosts pushing back | Why |
|---|---|---|---|---|---|---|
| Debunking the Solo-Founder Billion-Dollar Telehealth Unicorn | 7 | 0 | 0 | 0 | Coogan breaks down the financial reality behind the viral New York Times story about MedV, dissecting the difference between GMV run-rate and true enterprise market cap valuation. Hays and the other co-host fully agree and validate his framing without dissent. | |
| Unpacking MedV's Thin Margins and Outsourced Operations | 7 | 0 | 0 | 0 | Coogan details MedV's supply chain dependencies on third parties like CareValidate and OpenLoop Health, explaining how digital customer acquisition costs and pharmaceutical margins leave the business with thin net earnings. Hays contributes collaboratively to calculate potential EBITDA ranges. | |
| FDA Warning Letters and Lessons from the Nicotine Industry | 8 | 0 | 0 | 0 | Coogan draws on his direct founder experience at Lucy Nicotine to explain FDA warning letters, regulatory categories, and marketing compliance gray zones. Hays builds on this analysis by drawing parallels to how untraceable nicotine brands scale rapidly without generating durable enterprise value. | |
| Deceptive Marketing: 800 Fake Doctors and Class-Action Lawsuits | 7 | 0 | 0 | 0 | The hosts discuss MedV's deployment of 800 fake doctor profiles on Facebook and their pending California anti-spam class-action lawsuit. Coogan explains statutory damages and shares personal anecdotes regarding credential representations in healthcare advertising. | |
| The Legacy Playbook of Online Ad Arbitrage and Verification | 8 | 0 | 0 | 0 | Coogan breaks down historic 2014-era Facebook ad arbitrage tactics, describing the infamous Harvard-supplement-Johnny Depp cloaking formulas that generated tens of millions before ad networks introduced tighter scrapers. Hays concurs on the economics of influencer medical arbitrage. | |
| Solo Developer Case Study: Balatro and the Future of AI Software | 7 | 0 | 0 | 0 | Coogan examines genuine solo-developer successes, presenting Balatro's estimated $100M revenue and unit sales alongside an analysis of how AI can accelerate cross-platform porting and game logic. The studio team banters casually about internal AI simulations. |